Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-FR | Version v1-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2017-04-24 | 2017-04-06 |
| Drug Identification Number | 00578657 | 00578657 |
| Brand name | EPIPEN JR | EPIPEN JR |
| Common or Proper name | EpiPen Junior Auto-Injector | EpiPen Junior Auto-Injector |
| Company Name | MYLAN SPECIALTY LP | MYLAN SPECIALTY LP |
| Ingredients | EPINEPHRINE | EPINEPHRINE |
| Strength(s) | 0.5MG | 0.5MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAMUSCULAR | INTRAMUSCULAR |
| Packaging size | Each (0.15MG/0.3ML AUTO-INJECTOR) | Each (0.15MG/0.3ML AUTO-INJECTOR) |
| ATC code | C01CA | C01CA |
| ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2017-04-05 | 2017-04-05 |
| Estimated end date | 2017-04-26 | 2017-04-10 |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | As previously communicated, additional inventory of both EpiPen and EpiPen Junior were shipped to wholesalers this week. We are continuing to work with our manufacturing site to expedite our next deliveries and expect additional units to be available next week. | In light of the recent EpiPen and EpiPen Jr recall, we have distributed all of our EpiPen auto-injectors to wholesalers. This is an unexpected and exceptional situation. As we try to meet this increased demand, Pfizer expects to have short periods of constrained supply as incremental inventory is shipped from our manufacturing site. Additional inventory for both strengths is expected to be available next week. |
| Health Canada comments |